Live virus vaccines based on a yellow fever vaccine backbone: Standardized template with key considerations for a risk/benefit assessment

Vaccine

Volumn 33, Issue 1, 2015, Pages 62-72

  Monath, Thomas P ^a,j,k   Seligman, Stephen J ^b   Robertson, James S ^c   Guy, Bruno ^d   Hayes, Edward B ^e   Condit, Richard C ^f   Excler, Jean Louis ^g,h   Mac, Lisa Marie ⁱ   Carbery, Baevin ⁱ   Chen, Robert T ⁱ  

^a Kleiner Perkins Caufield & Byers   (United States)

^b NEW YORK MEDICAL COLLEGE   (United States)

^c NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

^d SANOFI PASTEUR   (France)

^e CENTRE FOR RESEARCH IN ENVIRONMENTAL EPIDEMIOLOGY CREAL   (Spain)

^f UNIVERSITY OF FLORIDA   (United States)

^g INTERNATIONAL AIDS VACCINE INITIATIVE   (United States)

^h US Military HIV Research Program (MHRP)   (United States)

ⁱ CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^j PaxVax Inc   (United States)

^k HOOKIPA BIOTECH AG   (Austria)

more..

Author keywords

Brighton Collaboration; Risk benefit assessment; Vaccine safety; Vaccines; Viral vector; Yellow fever vaccine

Indexed keywords

LIVE VACCINE; RECOMBINANT VACCINE; VIRUS ENVELOPE PROTEIN; VIRUS VECTOR; WEST NILE VACCINE; YELLOW FEVER VACCINE; DRUG CARRIER; VIRUS VACCINE;

ARTICLE; COMPARATIVE STUDY; DENGUE VIRUS; DRUG EFFICACY; DRUG SAFETY; GENE MUTATION; HUMAN; JAPANESE ENCEPHALITIS VIRUS; NONHUMAN; PEER REVIEW; PHASE 3 CLINICAL TRIAL (TOPIC); RISK ASSESSMENT; RISK BENEFIT ANALYSIS; STANDARDIZATION; VACCINATION; WEST NILE FLAVIVIRUS; YELLOW FEVER; GENE VECTOR; GENETICS; RANDOMIZED CONTROLLED TRIAL (TOPIC); YELLOW FEVER VIRUS;

DRUG CARRIERS; GENETIC VECTORS; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; VACCINES, ATTENUATED; VACCINES, SYNTHETIC; VIRAL VACCINES; YELLOW FEVER VIRUS;

EID: 84919360921     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.10.004     Document Type: Article

References (93)

1. Liniger M., Zuniga A., Naim H.Y. Use of viral vectors for the development of vaccines. Expert Rev Vaccines. 2007, 6(2):255-266.
2. Excler J.L., Parks C.L., Ackland J., Rees H., Gust I.D., Koff W.C. Replicating viral vectors as HIV vaccines: summary report from the IAVI-sponsored satellite symposium at the AIDS vaccine 2009 conference. Biologicals. 2010, 38(4):511-521.
3. Limbach K.J., Richie T.L. Viral vectors in malaria vaccine development. Parasite Immunol. 2009, 31(9):501-519.
4. Xing Z., Lichty B.D. Use of recombinant virus-vectored tuberculosis vaccines for respiratory mucosal immunization. Tuberculosis (Edinb) 2006, 86(3-4):211-217.
5. Naim H.Y. Applications and challenges of multivalent recombinant vaccines. Hum Vaccin Immunother. 2012, 9(3).
6. Johnson J.A., Barouch D.H., Baden L.R. Nonreplicating vectors in HIV vaccines. Curr Opin HIV AIDS 2013, 8(5):412-420.
7. Parks C.L., Picker L.J., King C.R. Development of replication-competent viral vectors for HIV vaccine delivery. Curr Opin HIV AIDS 2013, 8(5):402-411.
8. Wong G., Audet J., Fernando L., Fausther-Bovendo H., Alimonti J.B., Kobinger G.P., et al. Immunization with vesicular stomatitis virus vaccine expressing the Ebola glycoprotein provides sustained long-term protection in rodents. Vaccine. 2014, 32(43):5722-5729.
9. Mullard A. Experimental Ebola drugs enter the limelight. Lancet. 2014, 384(9944):649.
10. WHO Initiative for Vaccine Research. WHO informal consultation on characterization and quality aspect of vaccines based on live viral vectors December 2003. Accessed from: http://www.who.int/vaccine_research/documents/vvreport/en/index1.html on 30 October 2014.
11. Amarasinghe A., Black S., Bonhoeffer J., Carvalho S.M., Dodoo A., Eskola J., et al. Effective vaccine safety systems in all countries: a challenge for more equitable access to immunization. Vaccine. 2013, 31(Suppl 2):B108-B114.
12. MacDonald N.E., Smith J., Appleton M. Risk perception, risk management and safety assessment: what can governments do to increase public confidence in their vaccine system?. Biologicals. 2012, 40(5):384-388.
13. Chen R.T., Hibbs B. Vaccine safety: current and future challenges. Pediatr Ann. 1998, 27(7):445-455.
14. Kohl K.S., Bonhoeffer J., Chen R., Duclos P., Heijbel H., Heininger U., et al. The Brighton Collaboration: enhancing comparability of vaccine safety data. Pharmacoepidemiol Drug Saf. 2003, 12(4):335-340.
15. Monath T.P., GM, Staples J.E., Barrett A.D. Yellow fever vaccine. Vaccines 2012, 870-968. Saunders, China. 6th ed. S.A. Plotkin, W.A. Orenstein, P.A. O (Eds.).
16. Meeting of the Strategic Advisory Group of Experts on immunization, April 2013 - conclusions and, recommendations., Wkly Epidemiol. Rec. 2013, 88(20):201-206.
17. Vasconcelos P.F., Luna E.J., Galler R., Silva L.J., Coimbra T.L., Barros V.L., et al. Serious adverse events associated with yellow fever 17DD vaccine in Brazil: a report of two cases. Lancet. 2001, 358(9276):91-97.
18. Martin M., Tsai T.F., Cropp B., Chang G.J., Holmes D.A., Tseng J., et al. Fever and multisystem organ failure associated with 17D-204 yellow fever vaccination: a report of four cases. Lancet. 2001, 358(9276):98-104.
19. Chan R.C., Penney D.J., Little D., Carter I.W., Roberts J.A., Rawlinson W.D. Hepatitis and death following vaccination with 17D-204 yellow fever vaccine. Lancet. 2001, 358(9276):121-122.
20. Seligman S.J. Risk groups for yellow fever vaccine-associated viscerotropic disease (YEL-AVD). Vaccine. 2014, 32:5769-5775.
21. Seligman S.J. Yellow fever virus vaccine-associated deaths in young women. Emerg Infect Dis. 2011, 17(10):1891-1893.
22. Barwick Eidex R., Yellow Fever Vaccine Safety Working G. History of thymoma and yellow fever vaccination. Lancet. 2004, 364(9438):936.
23. Gershman M.D., Staples J.E., Bentsi-Enchill A.D., Breugelmans J.G., Brito G.S., Camacho L.A., et al. Viscerotropic disease: case definition and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine. 2012, 30(33):5038-5058.
24. Rice C.M., Lenches E.M., Eddy S.R., Shin S.J., Sheets R.L., Strauss J.H. Nucleotide sequence of yellow fever virus: implications for flavivirus gene expression and evolution. Science. 1985, 229(4715):726-733.
25. Durbin A.P., Kirkpatrick B.D., Pierce K.K., Elwood D., Larsson C.J., Lindow J.C., et al. A single dose of any of four different live attenuated tetravalent dengue vaccines is safe and immunogenic in flavivirus-naive adults: a randomized, double-blind clinical trial. J Infect Dis. 2013, 207(6):957-965.
26. Chen RT, Carbery B, Mac L, Berns KI, Chapman L, Condit RC, et al. The Brighton Collaboration Viral Vector Vaccine Safety Working Group (V3SWG). Vaccine. 2014 In press, Doi: 10.1016/j.vaccine.2014.09.035.
27. Lindsey N.P., Schroeder B.A., Miller E.R., Braun M.M., Hinckley A.F., Marano N., et al. Adverse event reports following yellow fever vaccination. Vaccine. 2008, 26(48):6077-6082.
28. Cottin P., Niedrig M., Domingo C. Safety profile of the yellow fever vaccine Stamaril(R): a 17-year review. Expert Rev Vaccines 2013, 12(11):1351-1368.
29. Whittembury A., Ramirez G., Hernandez H., Ropero A.M., Waterman S., Ticona M., et al. Viscerotropic disease following yellow fever vaccination in Peru. Vaccine. 2009, 27(43):5974-5981.
30. Breugelmans J.G., Lewis R.F., Agbenu E., Veit O., Jackson D., Domingo C., et al. Adverse events following yellow fever preventive vaccination campaigns in eight African countries from 2007 to 2010. Vaccine. 2013, 31(14):1819-1829.
31. Kengsakul K., Sathirapongsasuti K., Punyagupta S. Fatal myeloencephalitis following yellow fever vaccination in a case with HIV infection. J Med Assoc Thai. 2002, 85(1):131-134.
32. Martins R.M.M.M., Santos E.M., Cruz R.L.S., Santos P.G., e.a.Carvalho S.M.D. Yellow fever vaccine post-marketing surveillance in Brazil. Procedia Vaccinol. 2010, (2):178-183.
33. Veit O., Niedrig M., Chapuis-Taillard C., Cavassini M., Mossdorf E., Schmid P., et al. Immunogenicity and safety of yellow fever vaccination for 102 HIV-infected patients. Clin Infect Dis. 2009, 48(5):659-666.
34. Summary information on referral opinion pursuant to article 30 of council directive 2001/83/EC for stamaril and associated names 2006, 1. Committee for Medicinal Products for Human Use (CHMP), Committee for Medicinal Products for Human Use (CHMP), London, (See Annex I).
35. Transmission of yellow fever vaccine virus through breast-feeding-Brazil, 2009. MMWR Morb Mortal Wkly Rep 2010, 59(5):130-132. Centers for Disease, Control and Prevention.
36. Khromava A.Y., Eidex R.B., Weld L.H., Kohl K.S., Bradshaw R.D., Chen R.T., et al. Yellow fever vaccine: an updated assessment of advanced age as a risk factor for serious adverse events. Vaccine 2005, 23(25):3256-3263.
37. Monath T.P., Barrett A.D. Pathogenesis and pathophysiology of yellow fever. Adv Virus Res. 2003, 60:343-395.
38. Monath T.P., Liu J., Kanesa-Thasan N., Myers G.A., Nichols R., Deary A., et al. A live, attenuated recombinant West Nile virus vaccine. Proc Natl Acad Sci U S A. 2006, 103(17):6694-6699.
39. Guy B., Guirakhoo F., Barban V., Higgs S., Monath T.P., Lang J. Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue: West Nile and Japanese encephalitis viruses. Vaccine 2010, 28(3):632-649.
40. Monath T.P. Neutralizing antibody responses in the major immunoglobulin classes to yellow fever 17D vaccination of humans. Am J Epidemiol. 1971, 93(2):122-129.
41. Murray K., Walker C., Herrington E., Lewis J.A., McCormick J., Beasley D.W., et al. Persistent infection with West Nile virus years after initial infection. J Infect Dis. 2010, 201(1):2-4.
42. Gritsun T.S., Frolova T.V., Zhankov A.I., Armesto M., Turner S.L., Frolova M.P., et al. Characterization of a siberian virus isolated from a patient with progressive chronic tick-borne encephalitis. J Virol. 2003, 77(1):25-36.
43. Domingo C., Yactayo S., Agbenu E., Demanou M., Schulz A.R., Daskalow K., et al. Detection of yellow fever 17D genome in urine. J Clin Microbiol. 2011, 49(2):760-762.
44. McGee C.E., Tsetsarkin K., Vanlandingham D.L., McElroy K.L., Lang J., Guy B., et al. Substitution of wild-type yellow fever Asibi sequences for 17D vaccine sequences in ChimeriVax-dengue 4 does not enhance infection of Aedes aegypti mosquitoes. J Infect Dis. 2008, 197(5):686-692.
45. Reid M., Mackenzie D., Baron A., Lehmann N., Lowry K., Aaskov J., et al. Experimental infection of Culex annulirostris. Culex gelidus, and Aedes vigilax with a yellow fever/Japanese encephalitis virus vaccine chimera (ChimeriVax-JE). Am J Trop Med Hyg. 2006, 75(4):659-663.
46. Bhatt T.R., Crabtree M.B., Guirakhoo F., Monath T.P., Miller B.R. Growth characteristics of the chimeric Japanese encephalitis virus vaccine candidate, ChimeriVax-JE (YF/JE SA14--14--2), in Culex tritaeniorhynchus, Aedes albopictus, and Aedes aegypti mosquitoes. Am J Trop Med Hyg. 2000, 62(4):480-484.
47. Johnson B.W., Chambers T.V., Crabtree M.B., Guirakhoo F., Monath T.P., Miller B.R. Analysis of the replication kinetics of the ChimeriVax-DEN 1, 2, 3, 4 tetravalent virus mixture in Aedes aegypti by real-time reverse transcriptase-polymerase chain reaction. Am J Trop Med Hyg. 2004, 70(1):89-97.
48. Higgs S., Vanlandingham D.L., Klingler K.A., McElroy K.L., McGee C.E., Harrington L., et al. Growth characteristics of ChimeriVax-Den vaccine viruses in Aedes aegypti and Aedes albopictus from Thailand. Am J Trop Med Hyg. 2006, 75(5):986-993.
49. Kazimirova M., Mantel N., Raynaud S., Slovak M., Ustanikova K., Lang J., et al. Evaluation of chimeric yellow fever 17D/dengue viral replication in ticks. Vector Borne Zoonotic Dis. 2012, 12(11):979-985.
50. Mason R.A., Tauraso N.M., Spertzel R.O., Ginn R.K. Yellow fever vaccine: direct challenge of monkeys given graded doses of 17D vaccine. Appl Microbiol. 1973, 25(4):539-544.
51. Pulendran B., Miller J., Querec T.D., Akondy R., Moseley N., Laur O., et al. Case of yellow fever vaccine--associated viscerotropic disease with prolonged viremia, robust adaptive immune responses, and polymorphisms in CCR5 and RANTES genes. J Infect Dis. 2008, 198(4):500-507.
52. Pulendran B. Learning immunology from the yellow fever vaccine: innate immunity to systems vaccinology. Nat Rev Immunol. 2009, 9(10):741-747.
53. Monath T.P. Treatment of yellow fever. Antiviral Res. 2008, 78(1):116-124.
54. Monath T.P. Recombinant, chimeric, live, attenuated vaccines against Flaviviruses and Alphaviruses. Replicating vaccines: a new generation 2010, 349-438. Burkhäuser Verlag, Basel. C. RRDPM (Ed.).
55. Arroyo J., Guirakhoo F., Fenner S., Zhang Z.X., Monath T.P., Chambers T.J. Molecular basis for attenuation of neurovirulence of a yellow fever Virus/Japanese encephalitis virus chimera vaccine (ChimeriVax-JE). J Virol. 2001, 75(2):934-942.
56. McGee C.E., Lewis M.G., Claire M.S., Wagner W., Lang J., Guy B., et al. Recombinant chimeric virus with wild-type dengue 4 virus premembrane and envelope and virulent yellow fever virus Asibi backbone sequences is dramatically attenuated in nonhuman primates. J Infect Dis. 2008, 197(5):693-697.
57. Dayan G.H., Pugachev K., Bevilacqua J., Lang J., Monath T.P. Preclinical and clinical development of a YFV 17 D-based chimeric vaccine against West Nile virus. Viruses 2013, 5(12):3048-3070.
58. Xie H., Cass A.R., Barrett A.D. Yellow fever 17D vaccine virus isolated from healthy vaccinees accumulates very few mutations. Virus Res. 1998, 55(1):93-99.
59. Seligman S.J., Gould E.A. Live flavivirus vaccines: reasons for caution. Lancet 2004, 363(9426):2073-2075.
60. Monath T.P., Kanesa-Thasan N., Guirakhoo F., Pugachev K., Almond J., Lang J., et al. Recombination and flavivirus vaccines: a commentary. Vaccine 2005, 23(23):2956-2958.
61. McGee C.E., Tsetsarkin K.A., Guy B., Lang J., Plante K., Vanlandingham D.L., et al. Stability of yellow fever virus under recombinatory pressure as compared with chikungunya virus. PLoS One. 2011, 6(8):e23247.
62. Taucher C., Berger A., Mandl C.W. A trans-complementing recombination trap demonstrates a low propensity of flaviviruses for intermolecular recombination. J Virol. 2010, 84(1):599-611.
63. Pugachev K.V., Schwaiger J., Brown N., Zhang Z.X., Catalan J., Mitchell F.S., et al. Construction and biological characterization of artificial recombinants between a wild type flavivirus (Kunjin) and a live chimeric flavivirus vaccine (ChimeriVax-JE). Vaccine 2007, 25(37-38):6661-6671.
64. Pugachev K.V., Ocran S.W., Guirakhoo F., Furby D., Monath T.P. Heterogeneous nature of the genome of the ARILVAX yellow fever 17D vaccine revealed by consensus sequencing. Vaccine. 2002, 20(7-8):996-999.
65. Liprandi F. Isolation of plaque variants differing in virulence from the 17D strain of yellow fever virus. J Gen Virol. 1981, 56(Pt 2):363-370.
66. Jennings A.D., Gibson C.A., Miller B.R., Mathews J.H., Mitchell C.J., Roehrig J.T., et al. Analysis of a yellow fever virus isolated from a fatal case of vaccine-associated human encephalitis. J Infect Dis. 1994, 169(3):512-518.
67. Galler R., Pugachev K.V., Santos C.L., Ocran S.W., Jabor A.V., Rodrigues S.G., et al. Phenotypic and molecular analyses of yellow fever 17DD vaccine viruses associated with serious adverse events in Brazil. Virology. 2001, 290(2):309-319.
68. Mantel N., Girerd Y., Geny C., Bernard I., Pontvianne J., Lang J., et al. Genetic stability of a dengue vaccine based on chimeric yellow fever/dengue viruses. Vaccine 2011, 29(38):6629-6635.
69. Guirakhoo F., Zhang Z.X., Chambers T.J., Delagrave S., Arroyo J., Barrett A.D., et al. Immunogenicity, genetic stability, and protective efficacy of a recombinant, chimeric yellow fever-Japanese encephalitis virus (ChimeriVax-JE) as a live, attenuated vaccine candidate against Japanese encephalitis. Virology. 1999, 257(2):363-372.
70. Pugachev K.V., Guirakhoo F., Ocran S.W., Mitchell F., Parsons M., Penal C., et al. High fidelity of yellow fever virus RNA polymerase. J Virol 2004, 78(2):1032-1038.
71. Barban V., Girerd Y., Aguirre M., Gulia S., Petiard F., Riou P., et al. High stability of yellow fever 17D-204 vaccine: a 12-year restrospective analysis of large-scale production. Vaccine. 2007, 25(15):2941-2950.
72. Seligman S.J. Constancy and diversity in the flavivirus fusion peptide. Virol J 2008, 5:27.
73. Long M.T., Gibbs E.P., Mellencamp M.W., Zhang S., Barnett D.C., Seino K.K., et al. Safety of an attenuated West Nile virus vaccine, live Flavivirus chimera in horses. Equine Vet J. 2007, 39(6):486-490.
74. Doblas A., Domingo C., Bae H.G., Bohorquez C.L., de Ory F., Niedrig M., et al. Yellow fever vaccine-associated viscerotropic disease and death in Spain. J Clin Virol. 2006, 36(2):156-158.
75. Monath T.P., Myers G.A., Beck R.A., Knauber M., Scappaticci K., Pullano T., et al. Safety testing for neurovirulence of novel live, attenuated flavivirus vaccines: infant mice provide an accurate surrogate for the test in monkeys. Biologicals. 2005, 33(3):131-144.
76. Arroyo J., Miller C., Catalan J., Myers G.A., Ratterree M.S., Trent D.W., et al. ChimeriVax-West Nile virus live-attenuated vaccine: preclinical evaluation of safety, immunogenicity, and efficacy. J Virol 2004, 78(22):12497-12507.
77. Monath T.P., Levenbook I., Soike K., Zhang Z.X., Ratterree M., Draper K., et al. Chimeric yellow fever virus 17D-Japanese encephalitis virus vaccine: dose-response effectiveness and extended safety testing in rhesus monkeys. J Virol 2000, 74(4):1742-1751.
78. Bente D.A., Melkus M.W., Garcia J.V., Rico-Hesse R. Dengue fever in humanized NOD/SCID mice. J Virol. 2005, 79(21):13797-13799.
79. Lobigs M., Larena M., Alsharifi M., Lee E., Pavy M. Live chimeric and inactivated Japanese encephalitis virus vaccines differ in their cross-protective values against Murray Valley encephalitis virus. J Virol 2009, 83(6):2436-2445.
80. Tesh R.B., Arroyo J., Travassos Da Rosa A.P., Guzman H., Xiao S.Y., Monath T.P. Efficacy of killed virus vaccine, live attenuated chimeric virus vaccine, and passive immunization for prevention of West Nile virus encephalitis in hamster model. Emerg Infect Dis 2002, 8(12):1392-1397.
81. Guirakhoo F., Pugachev K., Zhang Z., Myers G., Levenbook I., Draper K., et al. Safety and efficacy of chimeric yellow Fever-dengue virus tetravalent vaccine formulations in nonhuman primates. J Virol 2004, 78(9):4761-4775.
82. Guirakhoo F., Arroyo J., Pugachev K.V., Miller C., Zhang Z.X., Weltzin R., et al. Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine. J Virol 2001, 75(16):7290-7304.
83. Monath T.P., Soike K., Levenbook I., Zhang Z.X., Arroyo J., Delagrave S., et al. Recombinant, chimaeric live, attenuated vaccine (ChimeriVax) incorporating the envelope genes of Japanese encephalitis (SA14-14-2) virus and the capsid and nonstructural genes of yellow fever (17D) virus is safe, immunogenic and protective in non-human primates. Vaccine 1999, 17(15-16):1869-1882.
84. Guirakhoo F., Pugachev K., Arroyo J., Miller C., Zhang Z.X., Weltzin R., et al. Viremia and immunogenicity in nonhuman primates of a tetravalent yellow fever-dengue chimeric vaccine: genetic reconstructions, dose adjustment, and antibody responses against wild-type dengue virus isolates. Virology. 2002, 298(1):146-159.
85. Sabchareon A., Wallace D., Sirivichayakul C., Limkittikul K., Chanthavanich P., Suvannadabba S., et al. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet 2012, 380(9853):1559-1567.
86. Monath T.P., McCarthy K., Bedford P., Johnson C.T., Nichols R., Yoksan S., et al. Clinical proof of principle for ChimeriVax: recombinant live, attenuated vaccines against flavivirus infections. Vaccine 2002, 20(7-8):1004-1018.
87. Monath T.P., Guirakhoo F., Nichols R., Yoksan S., Schrader R., Murphy C., et al. Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen. J Infect Dis 2003, 188(8):1213-1230.
88. Morrison D., Legg T.J., Billings C.W., Forrat R., Yoksan S., Lang J. A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirus-naive adults. J Infect Dis. 2010, 201(3):370-377.
89. Capeding M.R., Tran N.H., Hadinegoro S.R., Ismail H.I., Chotpitayasunondh T., Chua M.N., et al. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet 2014, 384(9951):1358-1365.
90. da Costa V.G., Marques-Silva A.C., Floriano V.G., Moreli M.L. Safety, immunogenicity and efficacy of a recombinant tetravalent dengue vaccine: A meta-analysis of randomized trials. Vaccine 2014, 32(39):4885-4892.
91. Torresi J., McCarthy K., Feroldi E., Meric C. Immunogenicity, safety and tolerability in adults of a new single-dose, live-attenuated vaccine against Japanese encephalitis: Randomised controlled phase 3 trials. Vaccine 2010, 28(50):7993-8000.
92. Guy B., Nougarede N., Begue S., Sanchez V., Souag N., Carre M., et al. Cell-mediated immunity induced by chimeric tetravalent dengue vaccine in naive or flavivirus-primed subjects. Vaccine 2008, 26(45):5712-5721.
93. Smith H.L., Monath T.P., Pazoles P., Rothman A.L., Casey D.M., Terajima M., et al. Development of antigen-specific memory CD8+ T cells following live-attenuated chimeric West Nile virus vaccination. J Infect Dis. 2011, 203(4):513-522.